Compare Abeona Therapeutics Inc (ABEO) vs Ecolab Inc. (ECL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Ecolab Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.72 (market cap $373.32M), while Ecolab Inc. trades at $275.83 (market cap $79.67B). The key difference: Ecolab Inc. is far larger — about 213.4× Abeona Therapeutics Inc's market cap, and Ecolab Inc. pays a 1.03% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ECL | |
|---|---|---|
Market Cap | $373.32M | $79.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $308.35 |
52-Week Low | $4.17 | $245.73 |
Enterprise Value | $228.22M | $88.42B |
Dividend Yield | — | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ECL trades at $283.08, down 0.1% on the day, with a bullish technical signal supported by moving averages. The company reported Q1 2026 EPS of $1.70, meeting expectations, and maintains strong profitability with a net income margin of 12.8%. Recent acquisition of CoolIT for $4.75B enhances its AI cooling portfolio, positioning for long-term growth. Cash flow from operations remains robust at $3.0B in 2025, though net cash flow turned negative due to significant investing activities.
Outlook is positive with 73% analyst buy ratings and a consensus price target of $326.17, implying 15% upside. Risks include rising costs and integration challenges from acquisitions. The stock's high P/E of 38.39 suggests premium valuation, requiring sustained earnings growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →
